中国临床药理学杂志2011，Vol.27Issue(1)：3-6,4.
哌拉西林/舒巴坦治疗呼吸机相关性肺炎的临床疗效和微生物学评价
Assessing the effects of piperacillin/sulbactam in the treatment of ventilator-associated pneumonia
王满 1许力军 1关英慧 1金香 1张洪泉1
作者信息
- 1. 吉林大学,第一临床医院呼吸科,长春,130021
- 折叠
摘要
Abstract
Objective To evaluate the reliability of piperacillin/sulbactam on the patients with ventilator - associated pneumonia (VAP) with clinical efficacy and bacterial clearance rate. Methods A total of 106 patients with VAP were enrolled into this clinical study, including 50 cases in piperacillin/sulbactam group (PSB group) and 56 cases in piperacillin/tazobactam group (PTZ group). The clinical efficacy and bacterial clearance rate of piperacillin/sulbactam and piperacillin/tazobactam in the treatment of VAP were prospectively analyzed during the period of Oct 2009 to Oct 2010. Results The cure and effective rates were 46. 0％ and 76. 0％ in the PSB group and 48.2％ and 76. 8％ in the PTZ group, respectively. Conclusion Piperacillin/sulbactam is as effective as piperacillin/tazobactam for the treatment of VAP. Piperacillin/sulbactam exhibits good activity again common strains isolated from VAP.关键词
哌拉西林/舒巴坦/呼吸机相关性肺炎/细菌清除率分类
医药卫生引用本文复制引用
王满,许力军,关英慧,金香,张洪泉..哌拉西林/舒巴坦治疗呼吸机相关性肺炎的临床疗效和微生物学评价[J].中国临床药理学杂志,2011,27(1):3-6,4.
